Affibody Medical Investor Relations

Affibody AB and Daiichi Sankyo enter into a License Agreement regarding the Albumod™ platform


June 25, 2013

Solna, Sweden, June 25, 2013. Affibody is pleased to announce a collaboration with Daiichi Sankyo Company Limited (hereinafter Daiichi Sankyo; headquartered in Chuo Ward, Tokyo, TSE 4568).

Affibody AB and Daiichi Sankyo have signed a License Agreement regarding the use of Affibody’s proprietary Albumod™ platform which is designed to enhance the efficacy of biopharmaceuticals by extending their circulatory half-life.

The collaboration with Daiichi Sankyo further establishes our AlbumodTM platform as a leading half-life extension technology”, commented David Bejker, CEO of Affibody. “It is very rewarding to work with Daiichi Sankyo on a unique project targeting unmet medical needs.”

The technology will be applied on one undisclosed molecule from Daiichi Sankyo’s pipeline of proprietary protein therapeutics. Affibody will receive up-front and milestone payments as well as royalties on sales for licensing of the Albumod™ platform.

Further details of the agreement have not been disclosed.

About the Albumod™ platform
Affibody’s Albumod™ technology is designed to enhance the efficacy of biopharmaceuticals by extending their circulatory half-life, potentially allowing for less frequent dosing and lower peak concentrations in blood with a decreased risk for adverse events. Furthermore, the Albumod™ technology may potentially be used to evade an immune response. In addition to these possible patient safety benefits, the overall treatment costs may be reduced.

About Affibody
Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Affibody is developing a portfolio of innovative drug projects and, in addition, offers the half-life extension technology, Albumod™, for outlicensing.

Affibody has ongoing commercial relationships with several companies including Algeta, Amylin, Sobi, GE, Daewoong and Thermo Fisher.

Affibody was founded in 1998 by researchers from the Royal Institute of Technology and the Karolinska Institute and is based in Stockholm, Sweden. Major shareholders in the Company include HealthCap and Investor AB.

Further information can be found at: